Data gathered: November 27
AI Stock Analysis - Iovance Biotherapeutics (IOVA)
Analysis generated September 26, 2024. Powered by Chat GPT.
Iovance Biotherapeutics is a biotechnology company primarily focused on the development and commercialization of innovative cancer immunotherapy products. By leveraging cutting-edge research and development in cell-based therapies, Iovance aims to significantly impact the treatment landscape for various cancers. The company's leading pipeline candidate, Tumor-Infiltrating Lymphocytes (TIL) therapy, targets solid tumors, which sets it apart as a unique player in the oncology sector.
Stock Alerts - Iovance Biotherapeutics (IOVA)
 |
Iovance Biotherapeutics | November 27 Price is up by 5.3% in the last 24h. |
|
Iovance Biotherapeutics | November 25 Price is up by 6.4% in the last 24h. |
|
Iovance Biotherapeutics | November 18 Price is up by 5.1% in the last 24h. |
|
Iovance Biotherapeutics | November 17 AI Score is down by 20.9% in the last couple of days. |
Alternative Data for Iovance Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 115 | Sign up | Sign up | Sign up |
| Sentiment | 99 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 58 | Sign up | Sign up | Sign up |
| Google Trends | 32 | Sign up | Sign up | Sign up |
| Patents | 191 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 63 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 13,507 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,462 | Sign up | Sign up | Sign up |
| Twitter Mentions | 70 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 43 | Sign up | Sign up | Sign up |
| Linkedin Employees | 711 | Sign up | Sign up | Sign up |
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
| Price | $9.40 |
| Target Price | Sign up |
| Volume | 4,000,000 |
| Market Cap | $2.83B |
| Year Range | $7.28 - $15.36 |
| Dividend Yield | 0% |
| Analyst Rating | 90% buy |
| Industry | Biotechnology |
In the news
 |
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory OfficerNovember 26 - Yahoo |
 |
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look BackNovember 23 - Yahoo |
 |
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge FundsNovember 22 - Yahoo |
|
Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to AnalystsNovember 21 - Yahoo |
 |
LMR Partners LLP Sells 20,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)November 21 - ETF Daily News |
|
Iovance Biotherapeutics (NASDAQ:IOVA) vs. Genenta Science (NASDAQ:GNTA) Head-To-Head SurveyNovember 19 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 59M | 40M | 19M | -84M | -84M | -0.280 |
| Q2 '24 | 31M | 31M | -260,000 | -97M | -96M | -0.340 |
| Q1 '24 | 810,000 | 7.3M | -6.5M | -113M | -113M | -0.420 |
| Q4 '23 | 590,000 | 4.4M | -3.8M | -116M | -117M | -0.450 |
| Q3 '23 | 470,000 | 4.3M | -3.9M | -114M | -114M | -0.460 |
Insider Transactions View All
| Dukes Iain D. filed to buy 54,000 shares at $9.2. February 20 '24 |
| MCPEAK MERRILL A filed to buy 320,150 shares at $9.2. February 20 '24 |
| Rothbaum Wayne P. filed to buy 28,067,333 shares at $9.2. February 20 '24 |
| MCPEAK MERRILL A filed to buy 248,633 shares at $5.6. September 19 '23 |
| Rothbaum Wayne P. filed to buy 23,067,333 shares at $5.3. September 15 '23 |
Similar companies
Read more about Iovance Biotherapeutics (IOVA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Iovance Biotherapeutics?
The Market Cap of Iovance Biotherapeutics is $2.83B.
What is the current stock price of Iovance Biotherapeutics?
Currently, the price of one share of Iovance Biotherapeutics stock is $9.40.
How can I analyze the IOVA stock price chart for investment decisions?
The IOVA stock price chart above provides a comprehensive visual representation of Iovance Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Iovance Biotherapeutics shares. Our platform offers an up-to-date IOVA stock price chart, along with technical data analysis and alternative data insights.
Does IOVA offer dividends to its shareholders?
As of our latest update, Iovance Biotherapeutics (IOVA) does not offer dividends to its shareholders. Investors interested in Iovance Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Iovance Biotherapeutics?
Some of the similar stocks of Iovance Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.